3Q Revenues: $55.8 million (+11%)
3Q Loss: $2.1 million (loss of $5.9 million 3Q11)
YTD Revenues: $159.5 million (-1%)
YTD Loss: $5.7 million (loss of $7.9 million YTD11)
Comments: Total contract revenue for the quarter was $45.6 million, up 4%. Large Scale manufacturing revenue was $29.3 million (+14%). Discovery Services revenue was flat at $8.9 million. Development/Small-Scale Manufacturing revenue was $7.4 million (-20%). Royalty revenue in the quarter was $9.4 million (+45%) related to worldwide sales of Allegra, and certain generic forms of Allegra. Revenue in the quarter includes milestones totaling $0.8 million from the company’s 2005 licensing agreement with BMS.